Fu Hong Han Lin announced that recently, an international multi-center phase 2 clinical study of injectable HLX43 in advanced non-small cell lung cancer patients has completed the first patient administration in the US. The Phase 2 clinical study is also being carried out simultaneously in China. The company plans to conduct clinical trials in countries such as Australia and Japan when conditions are met.

Fu Hong Han Lin announced that recently, an international multi-center phase 2 clinical study of injectable HLX43 in advanced non-small cell lung cancer patients has completed the first patient administration in the US. The Phase 2 clinical study is also being carried out simultaneously in China. The company plans to conduct clinical trials in countries such as Australia and Japan when conditions are met.